Literature DB >> 17935854

Alternative lengthening of telomeres (ALT) and chromatin: is there a connection?

Thalia Nittis1, Lionel Guittat, Sheila A Stewart.   

Abstract

The acquisition of cellular immortality is a critical step in the tumorigenic process that requires stabilization of the telomeres, nucleoprotein structures at the termini of chromosomes. While the majority of human tumors stabilize their telomeres through activation of telomerase (hTERT), a significant portion (10-15%) utilize a poorly understood alternative mechanism of telomere maintenance referred to as ALT (Alternative Lengthening of Telomeres). Strikingly, the ALT mechanism is more prevalent in tumors arising from tissues of mesenchymal origin than in those of epithelial origin. This observation suggests that cell type specific mechanisms favor the activation of the ALT mechanism versus telomerase in human tumorigenesis. In addition, the presence of an alternative mechanism of telomere maintenance raises the possibility that telomerase-positive tumors undergoing anti-telomerase therapies might escape by activating the ALT pathway. For these reasons, delineating the ALT mechanism is critical for our understanding of the tumorigenic process and the development of ALT-specific anti-neoplastic therapies. Recent studies have demonstrated that epigenetic modifications at telomeres have a profound effect on telomere length, and may also be linked to the ALT mechanism. In this review we focus on these recent advances and their implications in telomere maintenance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17935854     DOI: 10.1016/j.biochi.2007.08.009

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  12 in total

1.  An mre11 mutation that promotes telomere recombination and an efficient bypass of senescence.

Authors:  Immanual S Joseph; Alpana Kumari; Mrinal K Bhattacharyya; Honghai Gao; Bibo Li; Arthur J Lustig
Journal:  Genetics       Date:  2010-04-26       Impact factor: 4.562

2.  Changed genome heterochromatinization upon prolonged activation of the Raf/ERK signaling pathway.

Authors:  Catherine Martin; Songbi Chen; Daniela Heilos; Guido Sauer; Jessica Hunt; Alexander George Shaw; Paul Francis George Sims; Dean Andrew Jackson; Josip Lovrić
Journal:  PLoS One       Date:  2010-10-12       Impact factor: 3.240

3.  Inhibition of human telomerase reverse transcriptase in vivo and in vitro for retroviral vector-based antisense oligonucleotide therapy in ovarian cancer.

Authors:  Z Qi; R Mi
Journal:  Cancer Gene Ther       Date:  2016-01-08       Impact factor: 5.987

Review 4.  Medical genetics and epigenetics of telomerase.

Authors:  Jillian E Koziel; Melanie J Fox; Catherine E Steding; Alyssa A Sprouse; Brittney-Shea Herbert
Journal:  J Cell Mol Med       Date:  2011-03       Impact factor: 5.310

5.  Antisense oligodeoxynucleotide against human telomerase reverse transcriptase inhibits the proliferation of Eca-109 esophageal carcinoma cells.

Authors:  Xiang-Kui Fan; Rui-Hua Yan; Bao-Jiang Li; Xiang-Ming Chen; Lin Wei; Zhou Wang
Journal:  Exp Ther Med       Date:  2014-08-11       Impact factor: 2.447

Review 6.  Diagnosis and treatment of ALT tumors: is Trabectedin a new therapeutic option?

Authors:  Luca Pompili; Carlo Leonetti; Annamaria Biroccio; Erica Salvati
Journal:  J Exp Clin Cancer Res       Date:  2017-12-22

7.  Cohesin SMC1beta protects telomeres in meiocytes.

Authors:  Caroline Adelfalk; Johannes Janschek; Ekaterina Revenkova; Cornelia Blei; Bodo Liebe; Eva Göb; Manfred Alsheimer; Ricardo Benavente; Esther de Boer; Ivana Novak; Christer Höög; Harry Scherthan; Rolf Jessberger
Journal:  J Cell Biol       Date:  2009-10-19       Impact factor: 10.539

8.  TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma.

Authors:  Mohamed Ali Mosrati; Annika Malmström; Malgorzata Lysiak; Adam Krysztofiak; Martin Hallbeck; Peter Milos; Anna-Lotta Hallbeck; Charlotte Bratthäll; Michael Strandéus; Marie Stenmark-Askmalm; Peter Söderkvist
Journal:  Oncotarget       Date:  2015-06-30

Review 9.  Integration of Telomere Length Dynamics into Systems Biology Framework: A Review.

Authors:  Lilit Nersisyan
Journal:  Gene Regul Syst Bio       Date:  2016-06-16

Review 10.  Epigenetic Regulation of Telomere Maintenance for Therapeutic Interventions in Gliomas.

Authors:  Elisabeth Naderlinger; Klaus Holzmann
Journal:  Genes (Basel)       Date:  2017-05-17       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.